(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.00%) $78.11
(0.79%) $2.16
(-0.32%) $2 301.10
(0.14%) $26.73
(-0.79%) $957.65
(0.03%) $0.929
(-0.11%) $10.86
(-0.01%) $0.797
(0.00%) $91.45
Quarter results today
(amc 2024-05-06)
Expected move: +/- 3.58%
0.23% $ 401.08
@ $398.20
Emitido: 3 may 2024 @ 10:36
Retorno: 0.72%
Señal anterior: may 3 - 09:31
Señal anterior:
Retorno: -0.83 %
Live Chart Being Loaded With Signals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation...
Stats | |
---|---|
Volumen de hoy | 1.06M |
Volumen promedio | 1.10M |
Capitalización de mercado | 103.60B |
EPS | $0 ( 2024-02-05 ) |
Próxima fecha de ganancias | ( $4.10 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 28.90 |
ATR14 | $8.08 (2.01%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Upadhyay Suketu | Buy | 1 001 | Common Stock |
2024-05-01 | Upadhyay Suketu | Sell | 1 168 | Common Stock |
2024-05-01 | Upadhyay Suketu | Buy | 1 168 | Deferred Stock Units |
2024-05-01 | Thornberry Nancy | Buy | 501 | Common Stock |
2024-05-01 | Thornberry Nancy | Buy | 1 571 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-3.22 |
Last 100 transactions |
Buy: 192 573 | Sell: 204 506 |
Volumen Correlación
Vertex Pharmaceuticals Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas | |
---|---|
GETVV | -0.979 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vertex Pharmaceuticals Correlación - Moneda/Commodity
Vertex Pharmaceuticals Finanzas
Annual | 2023 |
Ingresos: | $9.84B |
Beneficio Bruto: | $8.58B (87.17 %) |
EPS: | $14.05 |
FY | 2023 |
Ingresos: | $9.84B |
Beneficio Bruto: | $8.58B (87.17 %) |
EPS: | $14.05 |
FY | 2022 |
Ingresos: | $8.93B |
Beneficio Bruto: | $7.85B (87.90 %) |
EPS: | $12.97 |
FY | 2021 |
Ingresos: | $7.57B |
Beneficio Bruto: | $6.67B (88.06 %) |
EPS: | $9.09 |
Financial Reports:
No articles found.
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico